Innate Pharma S.A.
IPHA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $13 | $52 | $58 | $12 |
| % Growth | -75.7% | -10% | 376.2% | – |
| Cost of Goods Sold | $0 | $56 | $52 | $47 |
| Gross Profit | $13 | $6 | $6 | -$22 |
| % Margin | 100% | 10.8% | 10.4% | -184.1% |
| R&D Expenses | $52 | $56 | $52 | $47 |
| G&A Expenses | $12 | $12 | $14 | $16 |
| SG&A Expenses | $12 | $12 | $14 | $26 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $10 |
| Other Operating Expenses | $0 | -$49 | -$3 | -$47 |
| Operating Expenses | $64 | $18 | $63 | $26 |
| Operating Income | -$52 | -$13 | -$57 | -$48 |
| % Margin | -408.6% | -24.4% | -99.6% | -394.9% |
| Other Income/Exp. Net | $2 | $5 | -$1 | $2 |
| Pre-Tax Income | -$49 | -$8 | -$58 | -$45 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$49 | -$8 | -$58 | -$53 |
| % Margin | -392% | -14.6% | -100.7% | -436% |
| EPS | -0.61 | -0.09 | -0.73 | -0.57 |
| % Growth | -577.8% | 87.7% | -28.1% | – |
| EPS Diluted | -0.61 | -0.09 | -0.73 | -0.57 |
| Weighted Avg Shares Out | 81 | 84 | 80 | 80 |
| Weighted Avg Shares Out Dil | 81 | 84 | 80 | 80 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $3 | $1 | $0 |
| Interest Expense | $1 | $1 | $0 | $0 |
| Depreciation & Amortization | $2 | $5 | $45 | $5 |
| EBITDA | -$47 | -$2 | -$12 | -$43 |
| % Margin | -371.7% | -3.5% | -21.3% | -356.9% |